ArticleEndocrine journal2025

Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer.

Yomi Nakashima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.